NanoVibronix, Inc. (NAOV)
Stock Price Chart
Key Info
| Market Cap | 8.80M |
| Revenue (ttm) | 565,000 |
| Net Income (ttm) | -4.04M |
| Shares Out | 4.61M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Jul 31, 2020 |
| Last Price | $1.46 |
| Previous Close | $1.52 |
| Change ($) | -0.06 |
| Change (%) | -3.95% |
| Day's Open | 1.51 |
| Day's Range | 1.46 - 1.54 |
| Day's Volume | 38,881 |
| 52-Week Range | 1.32 - 3.50 |
More Stats
| Market Cap | 8.80M |
| Enterprise Value | 8.36M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 4.61M |
| Float | 3.44M |
| EPS (basic) | -0.58 |
| EPS (diluted) | -0.57 |
| FCF / Share | -0.53 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 7,363 |
| Short Ratio | 0.09 |
| Short % of Float | 0.72% |
| Beta | 0.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 15.58 |
| PB Ratio | 14.20 |
| Revenue | 565,000 |
| Operating Income | -3.84M |
| Net Income | -4.04M |
| Free Cash Flow | -3.83M |
| Net Cash | 443,000 |
| Net Cash / Share | 0.07 |
| Gross Margin | 49.73% |
| Operating Margin | -678.76% |
| Profit Margin | -714.30% |
| FCF Margin | -678.23% |
| ROA | -247.36% |
| ROE | -27,834.48% |
| ROIC | -2,070.10% |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.53 | 0.32 | 0.24 | 0.23 | 0.15 | 0.20 | 0.21 |
| Revenue Growth | 66.67% | 33.05% | 4.37% | 55.78% | -27.59% | -3.79% | - |
| Gross Profit | 0.28 | 0.16 | 0.15 | 0.14 | 0.10 | 0.11 | 0.12 |
| Operating Income | -5.15 | -4.30 | -3.09 | -2.32 | -1.42 | -1.21 | -1.11 |
| Net Income | -5.79 | -4.15 | -4.97 | -2.83 | -2.88 | -2.65 | -1.99 |
| Shares Outstanding | 6.94 | 6.45 | 4.96 | 4.58 | 3.54 | 0.16 | 0.16 |
| Earnings Per Share | -0.83 | -0.64 | -1.17 | -0.62 | -0.82 | -17.08 | -12.83 |
| Operating Cash Flow | -3.87 | -3.55 | -2.18 | -1.53 | -1.48 | -0.90 | -0.60 |
| Capital Expenditures | - | -0.01 | - | -0.01 | - | - | -0.01 |
| Free Cash Flow | -3.87 | -3.56 | -2.18 | -1.54 | -1.48 | -0.90 | -0.61 |
| Cash & Equivalents | 1.34 | 0.90 | 4.36 | 0.11 | 1.61 | 0.09 | 0.09 |
| Total Debt | - | - | - | - | - | 4.62 | 3.11 |
| Net Cash / Debt | 1.34 | 0.90 | 4.36 | 0.11 | 1.61 | -4.53 | -3.01 |
| Assets | 2.04 | 1.58 | 4.87 | 0.49 | 1.98 | 0.72 | 0.69 |
| Liabilities | 0.69 | 1.12 | 1.23 | 2.99 | 2.19 | 6.34 | 3.99 |
| Book Value | 1.35 | 0.46 | 3.63 | -2.50 | -0.21 | -5.62 | -3.30 |
Company Profile
Company Details
| Full Name | NanoVibronix, Inc. |
| Country | United States |
| Employees | 10 |
| CEO | Brian M. Murphy |
Stock Information
| Ticker Symbol | NAOV |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: NAOV |
Description
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.